3 ms·
> and one of them went to someone with self-admittedly "very mild symptoms," In fairness, the monoclonal antibodies have been shown to be ineffective when give
by mlyle 6y ago
> and one of them went to someone with self-admittedly "very mild symptoms,"
In fairness, the monoclonal antibodies have been shown to be ineffective when given by the point symptoms are severe. To save any lives, you'll need to give them to people with mild to moderate symptoms but significant risk factors.
e.g. "...Casirivimab and imdevimab are not authorized for patients who are hospitalized due to COVID-19 or require oxygen therapy due to COVID-19. A benefit of casirivimab and imdevimab treatment has not been shown in patients hospitalized due to COVID-19. Monoclonal antibodies, such as casirivimab and imdevimab, may be associated with worse clinical outcomes when administered to hospitalized patients with COVID-19 requiring high flow oxygen or mechanical ventilation...." https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-monoclonal-antibodies-treatment-covid-19 https://www.fda.gov/news-events/press-announcements/coronavi...
Of course, this really sucks, because there's nowhere near enough to give to everyone who's high risk and has early COVID, while there might eventually be enough to give to people with severe COVID.